Aim: To clarify the differences in overall survival (OS) depending on the presence or
absence of hypomagnesemia and the type of epidermal growth factor receptor antibody as …

Currently, there are a few systemic treatment options for patients with metastatic colorectal
cancer (mCRC). Targeted therapy used in this setting includes the use of monoclonal …

Hypomagnesemia is a recognized side-effect of cetuximab-or panitumumab-based
chemotherapy for metastatic colorectal cancer (mCRC). The clinical relevance of …

Purpose Anti-EGFR monoclonal antibody is effective for KRAS wild-type metastatic
colorectal cancer (mCRC), but frequently causes several adverse reactions, including …

Methods: Retrospectively, we analyzed patients diagnosed with K-RAS wild-type mCRC
from January 2010 to December 2015, treated with cetuximab-plus irinotecan-based …

Background Cetuximab-induced hypomagnesemia has been associated with improved
clinical outcomes in advanced colorectal cancer (CRC). We explored this relationship from a …

3564 Background: KRAS wild-type mutational status is necessary but not sufficient to get
benefit from EGFR inhibition. Predictive markers are currently being evaluated including …

Background Cetuximab has been shown to be clinically active when given in combination
with irinotecan in patients with irinotecan-refractory metastatic colorectal cancer (mCRC) …

Purpose Although anti-EGFR monoclonal antibodies, including cetuximab and
panitumumab, are highly effective in KRAS wild-type advanced colorectal cancer, these …

In this case report, we describe a patient who remains in complete remission two years after
the discontinuation of anti-EGFR monotherapy as a third-line treatment, accompanied by …